About Ebb Health
Ebb Health is developing an investigational, drug-free device for neuropathic pain. It designed the product with input from people who live with nerve pain and aims to make it affordable.
The Portland company is an Oregon Bioscience Incubator client. It reached the early-stage final at the 2026 Bend Venture Conference, but its device is not FDA cleared or available for sale in the United States.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jan 5, 2026 | Oct 26, 2026 | $550,000of $900K target | 5 | $110K | Simple Agreement for Future Equity (SAFE)Rule 506(b) | Form D ↗ |
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Why Investors Backed Ebb Health
Ebb Health is building a drug-free device for people with nerve pain. It is gaining traction, advancing to the final round of a regional startup competition. But it has not revealed how the device works or published any clinical results.
The problem it targets
Neuropathic pain can interfere with everyday life. Drug treatments may not suit every patient. Ebb Health's option is non-invasive and intended for long-term relief.
What the product does
Ebb Health's device is precise and designed for patients to control. Its public pages do not explain the treatment mechanism or the product's form.
Progress so far
Only five companies reached that final. Ebb Health advanced from the semifinal in September 2026. The company has not named customers, reported revenue or published clinical study results.
We wrote this summary from public statements by Ebb Health and its investors. It is not investment advice.
Ebb Health in the News
Leadership Team
Executive officers and directors listed on Ebb Health's Form D filed Oct 26, 2026.
